dengu
mosquitoborn
diseas
caus
infect
dengu
viru
denv
estim
million
dengu
infect
occur
annual
million
manifest
clinic
nine
countri
experienc
dengu
epidem
current
dengu
endem
countri
primarili
tropic
subtrop
countri
four
dengu
viru
serotyp
genet
antigen
distinct
although
serotyp
elicit
similar
rang
diseas
manifest
infect
human
dengu
infect
caus
spectrum
ill
rang
asymptomat
fever
rash
joint
pain
mild
symptom
lifethreaten
dengu
haemorrhag
fever
dhf
dengu
shock
syndrom
dss
infect
one
denv
serotyp
induc
lifelong
immun
homolog
serotyp
three
heterolog
serotyp
fact
studi
shown
secondari
infect
differ
denv
serotyp
import
risk
factor
caus
sever
complic
dhf
dss
due
phenomenon
design
antibodi
depend
enhanc
ade
origin
antigen
sin
one
strategi
undertaken
halt
denv
infect
vector
control
aed
aegypti
aed
albopictu
primari
transmiss
vector
denv
strategi
fog
releas
genet
modifi
mosquito
could
lead
product
fewer
progeni
fail
lessen
mosquito
popul
wit
emerg
new
dengu
case
place
denguefre
less
dengu
case
past
activ
research
vaccin
develop
dengu
ongo
past
decad
develop
vaccin
held
back
sever
challeng
major
constraint
dengu
vaccin
develop
includ
lack
good
anim
model
complex
develop
vaccin
four
antigen
distinct
denv
serotyp
well
need
achiev
balanc
tetraval
respons
could
exhibit
signific
immun
four
virus
without
advers
effect
ade
origin
antigen
sin
first
dengu
vaccin
cydtdv
chimer
yellow
fever
virustetraval
dengu
vaccin
develop
sanofi
pasteur
licens
decemb
mexico
liveattenu
tetraval
vaccin
compris
structur
protein
premembran
envelop
protein
denv
base
yellow
fever
viru
backbon
approv
regimen
involv
three
dose
given
month
individu
year
age
outcom
phase
iii
clinic
trial
show
vaccin
success
reduc
dengu
hospit
howev
averag
efficaci
denv
low
especi
approxim
averag
efficaci
meanwhil
slightli
higher
respect
furthermor
previou
clinic
trial
reveal
cydtdv
vaccin
caus
elev
risk
hospit
children
less
nine
year
age
world
health
organ
therefor
recommend
use
cydtdv
vaccin
countri
epidemiolog
data
indic
high
burden
dengu
lack
effici
vector
control
strategi
uncertainti
longterm
protect
efficaci
cydtdv
vaccin
four
denv
serotyp
call
urgent
need
dengu
therapeut
especi
endem
countri
poor
resourc
set
antivir
drug
avail
present
support
treatment
emphasi
fluid
therapi
close
clinic
monitor
critic
phase
ill
cours
action
dengu
diseas
mani
antivir
candid
fail
reach
clinic
trial
due
poor
select
physiochem
pharmacokinet
properti
although
nucleosid
analog
balapiravir
enter
preclin
anim
safeti
studi
clinic
trial
termin
due
lack
potenc
balapiravir
instanc
improv
clinic
virolog
paramet
patient
phase
ii
clinic
trial
although
shown
good
vitro
antivir
activ
valu
denv
infect
assay
use
primari
human
macrophag
treatment
denvinfect
mice
anoth
nucleosid
analog
hand
complet
prevent
mice
death
sever
advers
event
observ
rat
dog
two
week
oral
dose
likewis
antidenv
candid
includ
chloroquin
prednisolon
celgosivir
lovastatin
gone
clinic
trial
fail
meet
defin
primari
end
point
wherebi
neither
signific
viremia
evid
benefici
effect
clinic
manifest
observ
present
two
candid
name
ivermectin
ketotifen
undergo
clinic
trial
trial
number
respect
howev
longterm
clinic
efficaci
remain
determin
contrast
small
molecul
peptid
gener
known
high
select
possess
rel
safe
characterist
make
attract
pharmacolog
candid
due
attract
pharmacolog
profil
review
highlight
current
statu
ration
drug
design
antivir
peptid
peptidomimet
therapeut
dengu
denv
envelop
posit
singlestrand
ss
rna
viru
classifi
genu
flaviviru
flavirida
famili
close
relat
virus
classifi
flaviviru
includ
yellow
fever
viru
yfv
west
nile
viru
wnv
japanes
enceph
viru
jev
zika
viru
dengu
virion
spheric
particl
approxim
nm
diamet
envelop
e
precursormembran
prm
membran
protein
locat
surfac
capsid
c
protein
sit
underneath
lipid
bilay
encapsul
viral
genom
denv
genom
kb
constitut
singl
open
read
frame
orf
encod
three
structur
protein
c
prmm
e
protein
follow
seven
nonstructur
ns
protein
figur
translat
polyprotein
cleav
cellular
signal
peptidas
viral
encod
proteas
gener
individu
protein
structur
protein
form
viral
particl
nonstructur
protein
particip
replic
invas
immun
system
design
peptid
therapeut
potenti
dengu
viru
necessari
understand
viral
replic
cycl
denv
infect
human
start
denvinfect
mosquito
bite
denv
replic
wide
spectrum
cell
includ
liver
spleen
lymph
node
kidney
organ
monocyt
macrophag
dendrit
cell
dc
shown
major
target
denv
life
cycl
dengu
viru
initi
viru
attach
interact
viral
surfac
protein
attachmentreceptor
molecul
surfac
target
cell
figur
receptor
recognit
believ
mediat
domain
iii
e
protein
enabl
viru
enter
host
cell
receptormedi
clathrindepend
endocytosi
primari
method
howev
studi
also
shown
viral
entri
could
occur
direct
fusion
viru
host
cell
intern
dissoci
e
homodim
take
place
result
acid
environ
endosom
subsequ
domain
ii
e
protein
project
outwardli
hydrophob
fusion
loop
domain
ii
insert
endosom
membran
trigger
domain
iii
fold
back
forc
viru
particl
endosom
membran
move
toward
fuse
togeth
fusion
viru
vesicular
membran
would
releas
nucleocapsid
cytoplasm
result
genom
uncoat
subsequ
viral
rna
genom
releas
viral
rna
translat
singl
polyprotein
process
co
posttransl
cellular
virusderiv
proteas
three
structur
protein
seven
ns
protein
figur
upon
protein
translat
ns
protein
initi
viral
genom
replic
intracellular
membran
result
product
viral
rna
strand
newli
synthes
rna
pack
c
protein
form
nucleocapsid
prm
e
protein
hand
form
heterodim
orient
lumen
er
believ
induc
curv
surfac
lattic
guid
virion
bud
henc
viru
assembl
bud
er
migrat
transgolgi
matur
process
slightli
acid
ph
transgolgi
network
prompt
dissoci
prme
heterodim
form
dimer
prm
cap
fusion
peptid
locat
domain
ii
e
protein
follow
cleavag
prm
argx
lysarg
arg
cellular
endoproteas
furin
x
amino
acid
produc
membraneassoci
pr
peptid
prm
pr
act
chaperon
stabil
e
protein
secretori
pathway
prevent
prematur
membran
fusion
end
pr
peptid
dissoci
upon
releas
progeni
exocytosi
peptid
biolog
activ
molecul
compris
combin
least
two
amino
acid
peptid
bond
contrast
larg
protein
smaller
size
consid
contain
less
amino
acid
residu
peptid
known
attract
pharmacolog
profil
due
highli
select
rel
safe
characterist
readili
exist
human
bodi
exert
divers
biolog
role
predominantli
signal
regulatori
molecul
varieti
physiolog
process
past
peptid
held
back
drug
develop
pipelin
due
instabl
wherebi
could
easili
degrad
least
proteas
human
bodi
nevertheless
number
technolog
breakthrough
advanc
revers
situat
result
spark
interest
peptid
drug
develop
current
technolog
allow
modif
peptid
creat
artifici
variant
improv
stabil
overcom
pharmacodynam
weak
instanc
advanc
automatedliquid
handl
devic
synthet
peptid
synthesi
mass
spectrometri
silico
drug
design
allow
highthroughput
drug
screen
addit
advanc
peptid
manipul
synthesi
damino
acid
cyclic
peptid
incorpor
chemic
nanocarri
increas
bioavail
peptid
current
ampl
exampl
efficaci
safe
peptid
drug
avail
market
great
success
achiev
peptid
drug
fuzeontm
enfuvirtid
synthet
peptid
block
viral
fusion
bind
polypeptid
chain
human
immunodefici
viru
hiv
envelop
protein
antivir
peptid
commercialis
antimicrobi
peptid
candid
arenicin
novexatin
lytixar
evalu
preclin
clinic
trial
myrcludex
b
antihepat
b
hepat
peptid
target
sodium
taurochol
cotransport
polypeptid
ntcp
liver
cell
also
studi
phase
ii
clinic
trial
present
valu
global
peptid
therapeut
market
predict
increas
us
billion
us
billion
year
least
therapeut
peptid
approv
us
food
drug
administr
fda
approxim
peptid
therapeut
evalu
clinic
trial
usapprov
peptid
drug
account
global
sale
us
billion
global
sale
us
million
exampl
therapeut
peptid
includ
glucagonlik
analogu
delet
peptid
insulin
delet
peptid
heat
shock
protein
use
wide
treatment
diabet
demonstr
potenti
import
peptid
pharmacolog
agent
addit
number
new
entiti
approv
fda
rapidli
decreas
year
number
public
side
effect
popular
small
molecul
increas
cancer
chemotherapeut
inhibitor
pharmaceut
industri
reviv
interest
peptid
potenti
drug
candid
good
pharmacolog
properti
new
technolog
mitig
weak
peptid
number
therapeut
peptid
candid
continu
grow
one
attract
approach
inhibit
viru
infect
block
cellular
receptor
attach
factor
mimick
cellular
receptor
henc
prevent
viru
attach
enter
host
cell
form
first
barrier
block
viral
infect
studi
shown
feasibl
approach
halt
viral
infect
pugach
et
al
liebermanblum
et
al
demonstr
small
molecul
inhibitor
maraviroc
success
inhibit
human
immunodefici
viru
type
infect
bind
coreceptor
host
cell
hand
myrcludex
b
lipomyristol
peptid
contain
homolog
amino
acid
residu
hepat
b
viru
protein
abl
bind
ntcp
host
cell
result
restrict
virion
uptak
host
cell
identifi
denv
receptor
attach
factor
mammalian
cell
review
pereralecoin
et
al
cruzoliveira
et
al
import
attach
factor
receptor
dendrit
cellspecif
intercellular
adhes
molecul
nonintegrin
dcsign
heparan
sulfat
mannos
receptor
laminin
receptor
tim
tam
protein
date
sever
small
molecul
identifi
receptor
antagonist
mimic
denv
instanc
ccchemokin
receptor
antagonist
metr
maraviroc
analogu
prevent
activ
reduc
denv
load
heparin
sulfat
mimet
fucoidan
shown
block
viral
entri
interestingli
best
knowledg
peptid
inhibitor
found
block
denv
infect
bind
cellular
attach
factor
receptor
repres
big
research
gap
prompt
research
investig
dcsign
type
ii
transmembran
protein
fall
categori
ctype
lectin
extracellular
domain
bind
specif
carbohydr
dcsign
shown
essenti
cellular
factor
requir
infect
ebola
viru
human
cytomegaloviru
cmv
dendrit
cell
studi
also
shown
dendrit
cell
abundantli
express
dcsign
highli
suscept
denv
infect
tassaneetrithep
et
al
valid
import
dcsign
denv
receptor
wherebi
transfect
dcsign
cell
result
denv
infect
dendrit
cell
block
antidcsign
prevent
denv
infect
result
suggest
dcsign
feasibl
target
design
therapi
prevent
denv
infect
furthermor
dendrit
cell
activ
captur
antigen
result
stimul
cell
produc
cytokin
chemokin
block
bind
denv
dcsign
prevent
denv
infect
well
initi
immun
respons
lead
sever
dengu
character
cytokin
storm
base
literatur
limit
dcsign
inhibitor
found
stop
denv
infect
studi
alen
et
al
evalu
inhibitori
properti
variou
carbohydratebind
agent
cba
mannosespecif
plant
lectin
use
rajidcsign
cell
line
result
show
hippeastrum
hybrid
hha
galanthu
nivali
gna
urtica
dioica
uda
abl
bind
envelop
denv
henc
prevent
subsequ
viral
attach
similarli
pradimicin
prm
smallsiz
nonpeptid
cba
shown
exert
antivir
activ
denv
bind
denv
envelop
monocytederiv
dendrit
cell
anoth
import
known
denv
receptor
glycosaminoglycan
gag
among
gag
famili
heparin
sulfat
hs
ubiquit
member
famili
put
receptor
denv
studi
shown
hs
act
first
interact
attach
factor
facilit
denv
bind
second
receptor
demonstr
denvh
interact
via
posit
charg
e
iii
residu
especi
ly
bind
neg
charg
hs
mani
heparan
mimet
identifi
block
denv
infect
lee
et
al
show
heparin
sulfat
mimet
phosphomannopentaos
sulfat
significantli
increas
surviv
rate
denvinfect
mice
anoth
studi
sulphat
polysaccharid
fucoidan
extract
marin
alga
cladosiphon
abl
inhibit
infect
bind
denv
envelop
protein
interestingli
talarico
et
al
show
iotacarrageenan
dlgalactan
hybrid
sulphat
polysaccharid
isol
red
seawe
gymnogongru
griffithsia
cryptonemia
crenulata
inhibit
denv
infect
viru
serotyp
host
cell
depend
manner
mani
heparin
mimet
includ
sulphat
galactomannan
curdlan
sulfat
sulphat
galactan
sulphat
chondroitin
sulfat
found
inhibit
denv
infect
antivir
peptid
identifi
either
bind
cellular
receptor
act
receptor
mimet
block
denv
entri
thu
far
likewis
best
knowledg
antivir
peptid
found
inhibit
denv
infect
target
receptor
includ
mannos
receptor
hsp
laminin
receptor
tim
tam
protein
furthermor
inhibitor
target
host
cellular
receptor
anticip
less
prone
develop
resist
compar
target
virus
therefor
may
serv
interest
research
gap
explor
although
studi
demonstr
denv
mainli
enter
host
cell
via
receptor
initiatedclathrin
mediat
endocytosi
viral
entri
via
clathrinindepend
endocyt
rout
also
observ
addit
evid
direct
entri
via
fusion
plasmat
membran
lead
direct
penetr
cytoplasm
without
undergo
endocytosi
also
describ
furthermor
evid
show
denv
abl
infect
varieti
cell
type
includ
isol
human
monkey
hamster
mosquito
via
differ
receptor
therefor
denv
entri
pathway
greatli
depend
cell
type
viral
strain
due
variabl
viral
entri
rout
broad
tissu
tropism
target
viral
structur
protein
easier
vastli
differ
cellular
receptor
denv
possess
capabl
util
wide
rang
cellular
receptor
pathway
enter
host
cell
viral
structur
protein
especi
e
protein
therefor
popular
target
antivir
inhibitor
interfer
virushost
interact
stop
subsequ
viral
entri
viral
infect
cycl
start
interact
viral
structur
protein
mediat
mainli
e
protein
host
cell
receptor
attach
factor
facilit
entri
viru
denv
e
protein
kda
size
compos
three
distinct
domain
name
domain
e
flank
dimer
domain
e
ii
contain
fusion
peptid
immunoglobulinlik
domain
e
iii
protrud
virion
surfac
follow
membran
proxim
stem
transmembran
anchor
figur
function
e
fulli
character
although
shown
involv
structur
rearrang
e
protein
intern
e
ii
contain
region
known
fusion
peptid
respons
viral
fusion
activ
e
domain
ii
also
contain
serotypeconserv
epitop
contribut
e
protein
dimer
previou
studi
shown
e
iii
respons
receptor
recognit
essenti
viral
attach
facilit
viral
entri
host
cell
receptormedi
clathrindepend
endocytosi
primari
method
addit
e
iii
also
harbour
serotypespecif
neutral
epitop
involv
receptor
recognit
attach
well
vital
role
mediat
viral
cellular
membran
fusion
releas
viral
genom
rna
viral
replic
e
glycoprotein
import
protein
facilit
viral
entri
henc
make
e
protein
good
antivir
target
stop
viral
entri
denv
e
structur
protein
well
determin
use
nuclear
magnet
reson
spectroscopi
xray
crystallographi
cryoelectron
microscopi
recent
advanc
understand
highresolut
e
structur
allow
research
util
inform
combin
silico
molecular
drug
design
method
search
potenti
antivir
candid
sever
research
group
util
differ
strategi
includ
silico
drug
design
screen
novel
antivir
peptid
e
protein
tabl
use
wimleywhit
interfaci
hydrophob
scale
wwih
combin
known
structur
data
e
protein
hrobowski
et
al
first
group
identifi
novel
peptid
correspond
stem
region
e
show
inhibit
peptid
suggest
function
sequenc
specif
mechan
scrambl
peptid
fail
inhibit
denv
infect
hypothes
peptid
might
interfer
intramolecular
interact
disrupt
structur
rearrang
fusion
protein
interact
target
cell
surfac
compon
exert
inhibitori
effect
mechan
action
peptid
evalu
later
studi
shown
peptid
inhibit
denv
infect
interact
directli
viru
particl
caus
format
hole
fivefold
vertic
viru
particl
led
releas
viral
genom
rna
exposur
viral
rna
exogen
rnase
likewis
schmidt
et
al
also
hypothes
prove
stem
peptid
could
inhibit
dengu
viru
infect
studi
set
overlap
peptid
base
stem
region
amino
acid
residu
synthes
test
bind
affin
solubl
form
e
se
cover
first
residu
e
via
fluoresc
polar
among
set
overlap
peptid
peptid
found
bind
select
postfus
se
concentr
halfmaxim
chang
fluoresc
polar
fp
kd
approxim
nm
scrambl
peptid
neither
bound
prefus
postfus
conform
se
schmidt
et
al
propos
peptid
inhibit
denv
infect
twostep
mechan
latestag
fusion
intermedi
wherebi
peptid
first
bind
nonspecif
viral
membran
follow
specif
interact
e
protein
e
protein
undergo
conform
rearrang
low
ph
interestingli
observ
reduct
hydrophob
chang
amino
acid
residu
greatli
reduc
inhibitori
properti
peptid
bind
affin
dengu
viru
e
protein
suggest
import
peptid
hydrophob
nonspecif
host
membran
interact
high
bind
affin
denv
e
protein
import
hydrophob
support
hrobowski
et
al
wherebi
novel
antivir
peptid
success
identifi
use
wimleywhit
interfaci
hydrophob
scale
wwih
screen
method
screen
method
calcul
slide
hydrophob
score
determin
segment
protein
propens
interact
membran
interfac
use
similar
strategi
anoth
studi
identifi
five
hydrophob
region
locat
e
protein
amino
acid
deriv
region
screen
via
wwih
optim
use
rapdf
bias
mont
carlo
method
result
identif
sever
novel
peptid
name
could
potenti
interrupt
proteinprotein
interact
denv
fusion
likewis
mani
antivir
peptid
identifi
virus
herp
simplex
viru
sever
acut
respiratori
syndrom
coronaviru
sar
human
cytomegaloviru
hcmv
rift
valley
fever
viru
rvfv
via
approach
valid
import
hydrophob
properti
antivir
peptid
addit
observ
mani
antivir
peptid
known
inhibit
entri
envelop
virus
cell
hydrophob
andor
amphipath
properti
facilit
interact
cellular
lipid
membran
interfac
besid
use
wwih
interfaci
helic
hydrophob
moment
ihhm
anoth
physiochem
determin
strategi
use
augment
peptidemembran
interfac
approach
quantifi
segreg
hydrophob
hydrophil
face
peptid
fold
structur
higher
ihhm
valu
indic
stronger
membran
interact
peptid
addit
badani
et
al
also
suggest
hydrophob
amphipath
critic
properti
peptid
interact
cellular
membran
therebi
inhibit
viral
entri
therefor
futur
drug
design
develop
research
could
consid
incorpor
hydrophob
amphipath
properti
antivir
peptid
enhanc
antivir
efficaci
previou
studi
shown
later
loop
locat
e
iii
play
import
role
virushost
receptor
interact
henc
make
interest
target
short
sequenc
later
loop
e
iii
use
target
screen
potenti
antivir
peptid
use
biomodroid
algorithm
four
differ
peptid
design
one
peptid
found
inhibit
tem
imag
indic
inhibit
entri
caus
structur
abnorm
alter
conform
chang
e
protein
contrari
panya
et
al
target
hydrophob
pocket
locat
domain
domain
ii
interfac
dv
e
protein
previou
studi
shown
shift
two
locat
hydrophob
pocket
essenti
caus
correct
conform
chang
viru
fusion
step
import
hydrophob
pocket
valid
sever
compound
target
hydrophob
pocket
abl
stop
denv
infect
use
autodock
cdocker
discoveri
studio
softwar
panya
et
al
found
dipeptid
ef
effect
antivir
peptid
inhibit
infect
valu
studi
shown
e
stem
region
well
conserv
among
flavivirus
includ
wnv
tickborn
enceph
viru
tbe
yfv
jev
therefor
antivir
peptid
target
one
denv
serotyp
might
possess
possibl
inhibit
denv
serotyp
close
relat
flavivirus
examin
hypothesi
schmidt
et
al
investig
antivir
potenti
stem
peptid
deriv
wnv
denv
amino
acid
residu
genom
four
denv
serotyp
synthes
along
solubl
tag
rgkgr
result
show
remain
strongest
inhibitor
four
dengu
serotyp
follow
nonetheless
stem
peptid
residu
relat
flavivirus
test
denv
infect
none
peptid
inhibit
denv
serotyp
might
due
variat
seven
residu
locat
ctermin
could
affect
nonspecif
interact
viral
membran
rather
poor
affin
e
protein
wnv
nearli
ident
bind
affin
trimer
se
valid
observ
mutagenesi
perform
confirm
residu
import
confer
antivir
activ
stem
peptid
wherebi
increas
hydrophob
would
increas
inhibitori
strength
hand
similar
situat
observ
hrobowski
et
al
wherebi
dn
peptid
peptid
sequenc
correspond
preanchor
stem
e
protein
highli
conserv
among
flavivirus
shown
inhibit
denv
also
demonstr
crossinhibitori
activ
wnv
inhibit
concentr
bai
et
al
found
peptid
isol
murin
brain
cdna
phage
display
librari
biopan
recombin
wnv
e
protein
test
inhibit
concentr
surfac
plasmon
reson
spr
show
bound
wnv
e
protein
kd
howev
specif
bind
site
e
protein
mode
action
unknown
peptid
block
denv
infect
bind
e
protein
opt
studi
set
peptid
comput
design
base
preentri
dimer
e
structur
peptid
specif
design
hing
domain
ii
first
domain
idomain
ii
connect
shown
display
respect
peptid
shown
bind
specif
affin
purifi
e
protein
imag
cryoem
suggest
peptid
might
caus
structur
deform
surfac
henc
interf
virushost
cell
bind
studi
peptid
inhibitor
also
reveal
peptid
inhibitor
abl
inhibit
antibodi
depend
enhanc
ade
effect
vitro
respect
recent
studi
chew
et
al
identifi
novel
peptid
peptid
ggww
biopan
randomis
phage
display
peptid
librari
purifi
viral
particl
approxim
inhibit
achiev
concentr
data
indic
peptid
ggww
inhibit
entri
hand
screen
commerci
cyclic
peptid
molecular
dock
result
identif
peptid
brain
natriuret
peptid
fragment
could
bind
e
protein
pki
valu
due
fact
data
obtain
via
silico
design
experi
requir
explor
inhibitori
potenti
peptid
denv
mani
studi
focus
denv
e
protein
due
natur
viru
structur
wherebi
e
protein
cover
surfac
area
viral
particl
vast
expand
knowledg
e
protein
nonetheless
prm
c
protein
feasibl
target
look
screen
antivir
peptid
prm
protein
kda
precursor
protein
approxim
kda
cleavag
prm
protein
cellular
proteas
furin
would
separ
prm
protein
pr
peptid
residu
ectodomain
residu
protein
residu
hydrophil
ntermin
region
protein
respons
code
glycosyl
pr
segment
prm
protein
prm
believ
protect
e
protein
conform
chang
matur
pathway
acid
environ
transgolgi
network
previou
studi
shown
prmcontainingviru
resist
low
ph
environ
upon
releas
matur
virion
pr
separ
leav
e
protein
surfac
matur
denv
recent
studi
peptid
inhibitor
mimick
conserv
ectodomain
protein
design
shown
inhibit
four
denv
serotyp
dock
result
indic
bound
interior
site
e
homodim
interact
site
nativ
protein
e
protein
addit
express
pr
protein
also
success
inhibit
viru
fusion
low
ph
stop
viral
infect
approxim
inhibit
achiev
data
indic
pr
peptid
interact
highli
conserv
histidin
substitut
alanin
led
disrupt
pre
interact
disrupt
could
result
distort
e
conform
therefor
interf
phtrigger
fusion
reaction
endosom
optim
could
carri
use
truncat
pr
peptid
identifi
amino
acid
residu
essenti
block
viral
infect
hand
denv
c
protein
approxim
kda
compos
four
region
arrang
antiparallel
homodim
structur
c
protein
contain
high
net
charg
asymmetr
distribut
basic
residu
lie
along
surfac
c
protein
orchestr
rna
bind
contrast
opposit
surfac
form
hydrophob
region
may
enabl
interact
lipid
configur
make
c
protein
essenti
viru
assembl
enabl
encapsul
ssrna
genom
form
nucleocapsid
despit
gener
understand
viral
rna
assembl
role
believ
hydrophob
region
ctermin
capsid
protein
contain
signal
sequenc
anchor
protein
endoplasm
reticulum
er
membran
partit
prm
protein
membran
ctermin
cleav
viral
proteas
form
matur
protein
viru
assembl
faustino
et
al
design
peptid
inhibitor
base
conserv
region
denv
c
protein
abl
interfer
interact
denv
c
protein
host
intracellular
lipid
droplet
shown
essenti
viral
particl
format
found
bind
forc
c
protein
lipid
droplet
reduc
pn
pn
addit
interestingli
despit
import
c
protein
viral
surviv
limit
antivir
peptid
design
c
protein
target
worth
look
viral
proteas
shown
serv
good
inhibitori
target
instanc
proteas
inhibit
shown
success
strategi
treat
hiv
infect
proteas
cleav
translat
polypeptid
chain
smaller
function
protein
therebi
allow
viru
particl
matur
inhibit
proteas
immatur
viru
particl
would
abl
transform
matur
virion
henc
obstruct
viral
replic
sever
proteas
inhibitor
discov
use
clinic
saquinavir
ritonavir
indinavir
nelfinavir
amprenavir
prodrug
fosamprenavir
lopinavir
atazanavir
darunavir
similarli
cofactor
protein
known
play
major
role
enzymat
activ
denv
infect
thu
make
ideal
antivir
target
denv
infect
translat
viral
genom
give
rise
polyprotein
contain
three
structur
seven
nonstructur
protein
polyprotein
cleav
individu
protein
viru
matur
host
proteas
signalas
furin
lumin
side
endoplasm
reticulum
well
viral
serin
proteas
proteas
cytoplasm
side
ensur
success
viral
replic
matur
denv
contain
trypsinlik
proteas
requir
cofactor
activ
cleav
denv
polyprotein
serhisasp
catalyt
triad
previou
studi
schuller
et
al
synthes
seri
tripeptid
aldehyd
inhibitor
wherebi
four
valu
rang
proteas
among
four
tripeptid
aldehyd
inhibitor
tripeptid
benzoylnlysargargh
tripeptid
phenylacetyllysargargh
report
potenti
antidenv
candid
respect
investig
reveal
bound
coval
proteas
result
format
close
conform
proteas
hydrophil
region
would
wrap
around
core
structur
analysi
proteasepeptid
complex
reveal
pocket
locat
proteas
could
act
new
antivir
target
drug
develop
anoth
proteas
inhibitor
aprotinin
larg
polypeptid
also
known
bovin
pancreat
trypsin
inhibitor
bpti
hypothes
form
multipl
interact
proteas
gain
inhibitori
activ
steric
hindranc
activ
site
contrast
tripeptid
requir
interact
direct
bind
observ
aprotinin
recent
studi
sever
cyclic
peptid
design
base
bind
loop
aprotinin
highli
similar
sequenc
nativ
cleavag
site
extend
posit
activ
site
proteas
result
indic
peptid
abl
show
good
inhibitori
properti
ki
valu
proteas
similar
bind
aprotinin
proteas
strong
hydrogen
bond
contribut
posit
observ
inhibitori
constant
valu
strong
aprotinin
ki
might
due
flexibl
cyclic
peptid
result
decreas
affin
proteas
nevertheless
studi
prove
feasibl
design
inhibitor
prime
nonprim
region
proteas
could
act
altern
candid
develop
therapeut
proteas
hand
nbenzoyl
cap
tetrapeptid
sequenc
nlelysargarg
previous
shown
favour
amino
acid
residu
subsit
proteas
bind
caviti
yusof
et
al
show
argarg
residu
posit
locat
next
cleavag
site
respons
high
bind
affin
proteas
li
et
al
found
ly
nle
norleucin
posit
essenti
high
bind
affin
interestingli
nitsch
et
al
show
remov
arginin
result
better
inhibitori
activ
nitsch
et
al
show
retropeptid
base
sequenc
arylcyanoacrylamid
group
ntermin
cap
possess
best
inhibit
activ
ki
valu
hypothes
arylcyanoacrylamid
moieti
mimic
first
arg
posit
arglysnl
tripeptid
bound
protein
pocket
proteas
unfortun
even
though
drug
candid
possess
good
bind
abil
signific
antivir
activ
cell
cultur
denv
therefor
nitsch
et
al
optim
lead
candid
via
structur
activ
relationship
assay
subsequ
studi
success
develop
thiazolidinedionebas
peptid
hybrid
hybrid
contain
hydrophob
group
better
ki
valu
nonetheless
drug
design
via
structurebas
activ
face
limit
due
differ
proteas
structur
deriv
crystal
versu
vivo
proteas
structur
therebi
antivir
candid
high
bind
affin
crystal
proteas
structur
might
bind
affin
proteas
vivo
overcom
challeng
nitsch
et
al
modifi
ntermin
cap
moieti
incorpor
membraneperm
peptid
increas
potenti
antivir
activ
peptid
hybrid
possess
best
antivir
activ
cell
cultur
found
rhodaninebas
peptid
hybrid
valu
ki
valu
studi
argli
residu
found
suffici
creat
high
target
affin
ki
valu
hand
behnam
et
al
util
bzarglysnl
core
sequenc
optim
chemic
structur
improv
antivir
potenti
proteas
tripeptid
hybrid
creat
combin
ether
thiazol
cap
tripeptid
hybrid
creat
combin
ether
cap
peptid
hybrid
success
show
improv
ki
valu
nm
nm
respect
thu
far
two
peptid
hybrid
possess
highest
bind
affin
proteas
nonetheless
deriv
possess
highest
bind
affin
lower
valu
reduc
viru
titer
compar
deriv
valu
deriv
deriv
found
potent
valu
respect
theoret
inhibitor
higher
bind
affin
target
would
result
higher
antivir
properti
contrast
direct
vitro
proteinpeptid
interact
assay
cellular
antivir
assay
cell
cultur
complic
factor
membran
permeabl
metabol
stabil
data
suggest
lipophil
tripeptid
hybrid
correl
well
observ
cellular
antivir
activ
might
influenc
fact
higher
polar
lower
lipophil
could
lead
weaker
membran
permeabl
case
tripeptid
hybrid
shown
lipophil
tripeptid
hybrid
moreov
data
also
indic
tripeptid
hybrid
possess
much
higher
halflif
minut
compar
tripeptid
hybrid
halflif
minut
metabol
clearanc
via
rat
liver
microsom
observ
might
offer
possibl
explan
higher
antivir
activ
tripeptid
hybrid
cellular
assay
compar
analogu
tripeptid
hybrid
possess
higher
bind
abil
proteas
vitro
anoth
studi
peptid
inhibitor
proteas
modifi
via
molecular
model
method
result
admetox
calcul
indic
peptid
inhibitor
bznlelysargbip
possess
best
pharmacokinet
properti
among
inhibitor
due
abil
better
absorb
intestin
remain
inact
central
nervou
system
result
support
use
bznlelysarg
lead
candid
drug
develop
denv
target
proteas
hand
sever
hexapeptid
deriv
proteas
cleavag
site
synthes
shown
inhibit
denv
low
micromolar
rang
among
candid
best
hexapeptid
inhibitor
deriv
region
ki
valu
likewis
sever
peptid
amid
inhibitor
mimick
region
design
two
peptid
inhibitor
found
inhibit
proteas
ki
valu
respect
tambunan
alamudi
design
sever
cyclopentapeptid
base
substrat
specif
proteas
cyclopentapeptid
ckrkc
found
best
candid
estim
free
bind
energi
kcalmol
ki
nonetheless
cyclopentapeptid
design
silico
vitro
cellbas
experi
requir
exploit
inhibitori
potenti
peptid
denv
similarli
velmurugan
et
al
found
hexapeptid
highest
bind
energi
kcalmol
proteas
investig
requir
verifi
antivir
potenti
via
vitro
studi
anoth
studi
natur
peptid
librari
compos
conotoxin
mixtur
peptid
neurotoxin
produc
cone
snail
use
screen
denv
proteas
cyclic
peptid
inhibitor
mria
deriv
conu
marmoreu
shown
possess
ki
valu
mutagenesi
studi
reveal
inhibitori
activ
mainli
mediat
disulphid
bond
loop
ly
residu
activ
site
proteas
previous
shown
prefer
ser
p
posit
optim
carri
chang
leu
ser
result
peptid
peptid
shown
stronger
inhibitori
activ
improv
ki
valu
respect
nonetheless
stabil
assay
show
half
inhibitori
activ
lost
inhibitori
activ
lost
incub
proteas
although
higher
ki
valu
compar
stabil
withstand
proteas
degrad
effici
cell
permeabl
vero
cell
shown
better
drug
candid
rothan
et
al
identifi
two
antivir
peptid
name
denv
proteas
previous
shown
cation
cyclic
peptid
possess
broad
antimicrobi
properti
differ
microorgan
addit
good
bind
affin
ki
valu
denv
proteas
abl
inhibit
denv
replic
rhesu
monkey
kidney
cell
contrari
circular
cation
peptid
shown
inhibit
proteas
result
indic
work
best
incub
simultan
treatment
give
reduct
viral
replic
hour
find
suggest
feasibl
candid
potenti
therapeut
drug
dengu
treatment
larg
multifunct
protein
play
import
role
viral
replic
modul
host
immun
respons
contain
rnadepend
rna
polymeras
domain
ctermin
end
essenti
viral
replic
methyltransferas
ntermin
region
rna
cap
function
essenti
viral
replic
therebi
make
promis
target
antivir
drug
develop
inhibit
polymeras
methyltransferas
function
activ
suppress
viru
growth
propag
host
cell
balapiravir
exampl
nucleosid
inhibitor
wherebi
correspond
adenosin
analogu
balapiravir
anoth
nucleosid
analogu
origin
develop
treatment
hepat
c
viru
howev
termin
due
sever
side
effect
balapiravir
fail
due
low
effici
clinic
trial
search
novel
antivir
peptid
methyltranseras
tambunan
colleagu
screen
commerci
cyclic
peptid
molecular
dock
result
reveal
two
potenti
ligand
name
endothelin
urotensin
ii
peptid
shown
bind
methyltranseras
form
stabl
complex
dock
result
suggest
endothelin
found
bind
sadenosyllmethionin
sam
site
kkalmol
urotensin
ii
bound
rnacap
site
kkalmol
nevertheless
vitro
verif
requir
elucid
antivir
potenti
inhibitor
despit
import
protein
limit
antivir
peptid
screen
studi
target
protein
perhap
due
lack
crystal
structur
contain
full
length
protein
recent
public
crystal
structur
protein
develop
antivir
peptid
target
protein
expect
number
limit
hinder
use
peptid
therapeut
drug
main
challeng
due
poor
stabil
bioavail
peptid
unmodifi
peptid
shown
commonli
degrad
quickli
human
serum
result
low
vivo
activ
nonetheless
variou
chemic
modif
appli
manipul
physicochem
properti
peptid
therebi
increas
stabil
bioavail
peptid
chemic
modif
approach
review
gentilucci
et
al
instanc
conjug
polym
polyethylen
glycol
peg
increas
molecular
weight
peptid
henc
enhanc
peripher
stabil
undergo
hydrolysi
brain
previou
studi
also
show
halfliv
unmodifi
peptid
less
hour
could
increas
approxim
hour
camid
nacetyl
cycliz
success
increas
halfliv
peptid
hour
hand
replac
arginin
residu
amino
acid
deriv
arginin
acid
agp
could
dramat
reduc
cleavag
peptid
trypsin
substitut
lamino
acid
damino
acid
increas
resist
degrad
bovin
pancreat
trypsin
human
elastas
stabil
damino
acid
substitut
increas
hour
compar
rapidli
cleav
two
enzym
addit
multipl
strategi
could
also
incorpor
peptid
drug
develop
enhanc
antivir
properti
peptid
includ
mutagenesi
assay
identifi
vital
amino
acid
respons
inhibitori
effect
addit
cell
penetr
peptid
increas
cell
permeabl
peptid
exampl
two
antivir
peptid
opt
opt
success
reduc
respect
amino
acid
optim
perform
via
residuespecif
allatom
probabl
discriminatori
function
approach
similarli
schmidt
cowork
success
enhanc
antivir
properti
identifi
peptid
optim
via
mutagenesi
assay
addit
solubl
tag
hand
due
hydrophil
conform
properti
peptid
cellular
uptak
peptid
constrain
oral
bioavail
peptid
therefor
limit
membran
barrier
overcom
challeng
cellpenetr
peptid
cpp
incorpor
peptid
sequenc
act
cargo
deliveri
carri
antivir
peptid
across
permeabl
barrier
enter
cell
exert
inhibitori
activ
instanc
conjug
tat
peptid
deriv
transcript
activ
protein
galactosidas
protein
enabl
deliveri
fusion
protein
tissu
mice
without
tat
peptideconjug
restrain
advanc
technolog
drawback
peptid
serv
antivir
agent
therefor
overcom
variou
strategi
turn
aid
develop
use
peptid
therapeut
develop
peptid
therapeut
drug
virus
promis
field
drug
discoveri
peptid
known
highli
specif
select
target
lower
toxic
low
accumul
tissu
make
good
candid
drug
develop
phenomenon
contrast
small
molecul
drug
wherebi
offtarget
toxic
biggest
drawback
small
molecul
drug
although
peptid
possess
sever
limit
could
overcom
via
chemic
modif
mani
peptid
shown
effect
demonstr
good
silico
vitro
bind
affin
viral
target
tabl
howev
mani
antivir
peptid
denv
test
cellbas
assay
none
evalu
vivo
studi
therefor
studi
focu
elucid
antivir
potenti
peptid
anim
model
mice
highli
suscept
denv
infect
lack
type
type
ii
ifn
receptor
furthermor
ideal
denv
inhibitor
need
effect
four
denv
serotyp
inhibitori
potenti
denv
serotyp
explor
mani
studi
describ
review
except
mechan
inhibit
peptid
well
defin
area
studi
perform
exploit
potenti
antivir
peptid
candid
moreov
commerci
avail
vaccin
cydtdv
unabl
achiev
maxim
protect
four
denv
serotyp
vector
control
strategi
fail
reduc
spread
denv
peptid
inhibitor
target
host
cell
viral
structur
protein
nonstructur
protein
may
help
overcom
dengu
infect
effect
antivir
vaccin
vector
control
fog
dengu
endem
countri
better
control
state
public
health
improv
